Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its blockbuster obesity drug Wegovy, helped overweight patients lower their weight by 20.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially approved for managing type 2 diabetes. While there is currently limited data on its risks and benefits for those with type 1 diabetes,

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%. The trial was testing a 7.2 milligram dose of the drug,

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the company said semaglutide 7.2 milligram (mg) injections over a 72-week period resulted in an average weight loss of 20.7%, better than the 17.5% weight loss achieved in a prior trial of semaglutide 2.4 mg injections.

The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug companies, including Rybelsus, another drug that works to combat diabetes and can lead to weight loss; Trelegy Ellipta, which treats chronic obstructive pulmonary disease and asthma; and Xtandi, which treats prostate cancer.